.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AK01_Pyrazinamide.Pyrazinamide .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AK01_Pyrazinamide.Pyrazinamide| name: | Pyrazinamide |
| ATC code: | J04AK01 | route: | oral |
| n-compartments | 1 |
Pyrazinamide is a synthetic pyrazine analogue antitubercular agent used primarily for the treatment of active tuberculosis as part of combination therapy. It is included in standard first-line regimens recommended by the World Health Organization (WHO). It is approved and widely used today.
Pharmacokinetics reported for healthy adult volunteers after single oral dose administration.
Abulfathi, AA, et al., & Reuter, H (2019). Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. Clinical pharmacokinetics 58(9) 1103–1129. DOI:10.1007/s40262-019-00764-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31049868
Sullins, AK, & Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatric drugs 15(2) 93–117. DOI:10.1007/s40272-013-0017-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23529866
Zvada, SP, et al., & Simonsson, US (2014). Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. The Journal of antimicrobial chemotherapy 69(5) 1339–1349. DOI:10.1093/jac/dkt524 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24486870